Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
E-pub ahead of print

Cerebral Oxygen Metabolism in Adults with Sickle Cell Disease

Research output: Contribution to journalJournal articleResearchpeer-review


  1. Quantification of cerebral perfusion and cerebrovascular reserve using Turbo-QUASAR arterial spin labeling MRI

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. European Ultrahigh-Field Imaging Network for Neurodegenerative Diseases (EUFIND)

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Prospective motion correction in single voxel spectroscopy at 7T using fat navigators and higher order shimming

    Research output: Contribution to conferenceConference abstract for conferenceResearchpeer-review

  4. Ultra-high field MR angiography in human migraine models: a 3.0 T/7.0 T comparison study

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Lena VáclavŮ
  • Jan Petr
  • Esben Thade Petersen
  • Henri Jmm Mutsaerts
  • Charles Bl Majoie
  • John C Wood
  • Ed VanBavel
  • Aart J Nederveen
  • Bart J Biemond
View graph of relations

In sickle cell disease (SCD), oxygen delivery is impaired due to anemia, especially during times of increased metabolic demand, and cerebral blood flow (CBF) must increase to meet changing physiologic needs. But hyperemia limits cerebrovascular reserve (CVR) and ischemic risk prevails despite elevated CBF. The cerebral metabolic rate of oxygen (CMRO2 ) reflects oxygen supply and consumption so may be more insightful than flow-based CVR measures for ischemic risk in SCD. We hypothesized that adults with SCD have impaired CMRO2 at rest and that a vasodilatory challenge with acetazolamide would improve CMRO2 . CMRO2 was calculated from CBF and oxygen extraction fraction (OEF), measured with arterial spin labeling and T2 -prepared tissue relaxation with inversion recovery (T2 -TRIR) MRI. We studied 36 adults with SCD without a clinical history of overt stroke and 9 healthy controls. As expected, CBF was higher in patients with SCD versus controls (mean ± standard deviation: 74±16 vs 46±5 mL/100g/min, P<.001), resulting in similar oxygen delivery (SCD: 377±67 vs controls: 368±42 μmol O2 /100g/min, P=.69). OEF was lower in patients versus controls (27±4 vs 35±4 %, P<.001), resulting in lower CMRO2 in patients versus controls (102±24 vs 127±20 μmol O2 /100g/min, P=.002). After acetazolamide, CMRO2 declined further in patients (P<.01) and did not decline significantly in controls (P=.78), indicating that forcing higher CBF worsened oxygen utilization in SCD patients. This lower CMRO2 could reflect variation between healthy and unhealthy vascular beds in terms of dilatory capacity and resistance whereby dysfunctional vessels become more oxygen-deprived, hence increasing the risk of localized ischemia. This article is protected by copyright. All rights reserved.

Original languageEnglish
JournalAmerican Journal of Hematology
Publication statusE-pub ahead of print - 9 Jan 2020

ID: 59013068